Big Expectations for the future of Opioid Induced Constipation Treatment Market

Transparency Market Research has published a new market report titled, “Opioid Induced Constipation Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023”. According to the report, the global opioid induced constipation treatment market was valued at US$0.4 bn in 2014 and is anticipated to expand at a CAGR of 31.2% from 2015 to 2023 to reach US$4.8 bn by 2023.

The report provides detailed analysis of current and emerging drugs for opioid induced constipation treatment, and the market is estimated based on type of drug class and dosage form of the drugs. Drug classes include mu-opioid receptor antagonist, chloride channel activator, and others based on their mechanism of action. Based on dosage form of drugs, the market has been segmented into solid, semi-solid, and liquid.

The chloride channel activator segment accounted for the largest share of the opioid induced constipation treatment market in 2014 due to first approval and launch of Amitiza in major countries. However, mu-opioid receptor antagonist was the fastest growing segment due to recent launch of the new drug Movantik and presence of pipeline drugs (naldemedine and other early stage drugs). Mu-opioid receptor antagonist drugs target the root cause of constipation by acting on specific peripheral opioid receptors, which revert the opioid action without affecting opioids analgesic action. Presently, Amitiza is the only available drug that belongs to the chloride channel activator class. However, mu-opioid receptor antagonist class consists of Movantik (AstraZeneca), Relistor (Valeant Pharmaceuticals, Inc.), and Naloxone. Additionally, naldemedine is in the late stage clinical trial. The drug is investigational, oral, mu-opioid receptor antagonist and is expected to launch in mid-2016. In August 2015, Shionogi’s naldemedine met primary and secondary endpoints in phase III clinical trial (COMPOSE II) to treat opioid induced constipation. Linaclotide is another potential drug, which is currently in phase II clinical trial. Phase I clinical trial (KODIAK16) is underway to assess the efficacy and safety of naloxegol in the treatment of opioid induced constipation in pediatric patients. The trial is expected to be completed in November 2017. Hence, launch of pipeline drugs during the forecast period is expected to boost the growth the PAMORA segment. The others segment includes Resolor (prucalopride), bulking agents (cellulose and psyllium), stool softeners (docusate), laxatives, and osmotic agents (lactulose, sorbitol, and polyethylene glycol). Major players in this segment are Boehringer Ingelheim GmbH and C.B. Fleet Company, Inc. Traditional laxatives are not legally approved for the treatment of opioid induced constipation. However, low cost of therapy, high awareness, and easy access to medicines accounted significant share of the opioid induced constipation treatment market. For instance, monthly cost of standard laxative therapy ranges from US$ 6 to US$ 80. However, monthly cost of Amitiza ranges from US$ 300 to US$ 400 and from US$ 600 to US$ 1000 for Relistor. Asia Pacific, Latin America, and Middle East & Africa are the major consumers of traditional medicines used to treat opioid induced constipation due to easy access, low cost, and less awareness about targeted therapy.

Furthermore, based on dosage form, the market has been segmented into solid, semi-solid, and liquid. The solid dosage form segment accounted for the largest share of the market in 2014. The segment is expected to maintain its leadership position during the forecast period. This is due to high patient compliance and launch of new drugs in solid form such as capsules, tablets, and pills. The semi-solid and liquid dosage form segments accounted for small shares of the market.

Get Free PDF Brochure for more Professional and Technical industry insights: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=6862

The number of players operating in the opioid induced constipation treatment market is small, while demand for the therapy is high. Major players operating in the global opioid induced constipation treatment market are AstraZeneca plc, Takeda Pharmaceutical Company Limited, Abbott Laboratories, Valeant Pharmaceuticals International, Inc., Bayer AG, C.B. Fleet Company, Inc., Boehringer Ingelheim GmbH, Daewoong Co. Ltd., and Cosmo Pharmaceuticals. Acquisitions and collaborations among major companies to commercialize OIC medicines are expected to boost the market during the forecast period. For instance, in March 2015, AstraZeneca and Daiichi Sankyo signed a co-commercialization agreement for Moventik in the U.S. In addition, in October 2014, Takeda and Sucampo entered into global license, development, and commercialization agreement for Amitiza. Hence, strategic agreements between companies are expected to drive the opioid induced constipation treatment market during the forecast period from 2015 to 2023.

Opioid Induced Constipation Treatment Market to Touch US$4.8 bn by 2023, Mu-opioid Receptor Antagonist to be Fastest-growing Segment

Commonly used opioids to treat moderate to severe pain are fentanyl, hydromorphone, methadone, morphine, oxycodone, and pethidine. Opioids play an important role in the management of chronic pain by acting on mu opioid receptors in the brain. However, these also bind to mu opioid receptors present in the intestine. Hence, patients taking opioids suffer from severe constipation known as opioid induced constipation (OIC). Chronic severe constipation further affects the lifestyle of patients, hence the need to prescribe adjacent therapy along with opioids to treat chronic constipation. Presently, usage of opioid to treat chronic cancerous and non-cancerous pain is limited to North America, Europe, and Australia due to high acceptance of opioids and increasing health care expenditure. Hence, these are the most attractive markets for opioid induced constipation treatment.

The global opioid induced constipation treatment market has been segmented based on drug class and dosage form of the drugs. Based on drug class, the market has been segmented into mu-opioid receptor antagonists, chloride channel activator, and others. The mu-opioid receptor antagonist segment consists of Moventik (AstraZeneca), Relistor (Valeant), and Naloxone. The chloride channel activator segment includes Amitiza (Takeda) and the others segment includes Resolor and traditional laxatives. Traditional laxatives such as bulking agents, osmotic agents, and stool softeners affect bowel movement. However, the effect is temporary and frequently induces undesired side effects. Hence, the others segment accounted for a small share of the global opioid induced constipation treatment market. The chloride channel activator segment accounted for the highest share of the global opioid induced constipation treatment market owing to high demand for Amitiza as single drug in the market. However, mu-opioid receptor antagonist is the fastest growing segment owing to recent launch of Moventik and presence of pipeline drugs (Naldemedine). Additionally, the class specifically targets peripheral mu-opioid receptors hence revert the action of opioid on peripheral receptors without affecting opioids central analgesics effect. Based on dosage form of the drugs, the market has been segmented into solid, semi-solid, and liquid. Major medicines for opioid induced constipation are available in the solid dosage form such as pills, tablets, and capsules. Hence, the solid dosage form segment accounted for the largest share of the market in 2014. The segment is anticipated to dominate the market during the forecast period. This is due to high patient compliance and less painful procedure than parenteral route. Liquid dosage form consists of emulsions, suspensions, syrups, and subcutaneous injections. The segment is expected to witness moderate growth during the forecast period.

Request free Sample pages of premium Research Report : http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=6862

Geographically, the opioid induced constipation treatment market has been classified into five major regions: North America, Europe, Asia Pacific, Latin America, and Rest of the World. North America accounted for the largest share of the market in 2014 and is expected to gain market share during the forecast period from 2015–2023. This is due to increase in the number of opioid induced constipation sufferers, approval and launch of drugs to treat OIC, availability of pipeline drugs, and favorable government initiatives. However, the market is witnessing slow growth in Asia Pacific, Latin America, and Rest of the World owing to low awareness about opioid induced constipation treatment, high cost of the therapy, and less penetration of opioid to treat chronic pain. Amendments in regulations in some countries over opioid use and patient-physician awareness are the major factors likely to increase uptake of opioid induced constipation medicines in Asia Pacific, Latin America, and Rest of the World.

The opioid induced constipation treatment market exhibits intense competition among the existing players. The players operating in the market are limited; however, a number of companies are interested to invest in the market due to increasing demand for the therapy. Major players operating in the global opioid induced constipation treatment market are AstraZeneca plc, Takeda Pharmaceutical Company Limited, Abbott Laboratories, Valeant Pharmaceuticals International, Inc., Bayer AG, C.B. Fleet Company, Inc., Boehringer Ingelheim GmbH, Daewoong Co. Ltd., and Cosmo Pharmaceuticals.